Author

Linda Rootkin

Institution: Health Innovation Manchester

Observed institutions: Novartis (United States), Health Innovation Manchester

ORCID: 0000-0001-8918-4325

Observed ORCID: 0000-0001-8918-4325

OpenAlex ID: A5066984789

The triple win – implementation science benefits patients, healthcare systems and industry alike

2022 · Melvin (Skip) Olson, Linda Rootkin · Journal of Comparative Effectiveness Research · 14

Implementation of inclisiran in United Kingdom primary care for patients with atherosclerotic cardiovascular disease or its-risk equivalents: rationale and design of Victorion-spirit, a pragmatic phase IIIb, randomised controlled study

2023 · Paul M. Wilson, Samantha Dixon, et al. · International Journal of Clinical Trials · 9

231 Evaluating the implementation of inclisiran in primary care (victorion-spirit): process evaluation findings from interviews with key stakeholders

2024 · Paul Wilson, Rebecca Elvey, et al. · Heart

Works count: 3

Citation count: 23

H-index: 2

I10-index: 1